Program
SHR-2004
A development code. Also written as “SHR-2004 injection” and “SAD, SHR-2004”.
In Jiangsu HengRui Medicine's pipeline, FXI
. Its studies are mostly in Venous Thrombosis · Atrial Fibrillation · Ovarian Neoplasms · Venous Thromboembolism, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 50 open or running | phase 3since Feb 9, 2025 | May 6, 2022 | none ahead |
- Named in Jiangsu HengRui Medicine’s own pipeline as
SHR-2004
, phase 3, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 6, 2022First study: phase 1 study in Venous ThrombosisFirst studyNCT05369767 · 64 enrolled · China
- Feb 22, 2023Phase 2 study in Prevention of Venous Thromboembolism After Knee ArthroplastyNCT05752461 · 353 enrolled · China
- Jan 12, 2024Phase 2 study in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer SurgeryNCT06220123 · 225 enrolled · China
- Feb 20, 2024Phase 1 study in Atrial FibrillationNCT06280768 · 10 enrolled · China
- Feb 9, 2025Phase 3 study in Venous ThrombosisNCT06825416 · 1,165 enrolled · China
TargetBeta
“FXI”the company's pipeline, read by Claude · source
Other programs on F11
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| milvexian | Bristol-Myers Squibb | phase 3 | 25 |
| abelacimab | anthos-therapeutics-inc | phase 3 | 8 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06825416Venous Thrombosis · China | 3 | Completed | Feb 15, 2026 | 1,165 |
| NCT06280768Atrial Fibrillation · China | 1 | Completed | Jan 10, 2025 | 10 |
| NCT06220123Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery · China | 2 | Completed | Dec 31, 2024 | 225 |
| NCT05752461Prevention of Venous Thromboembolism After Knee Arthroplasty · China | 2 | Completed | Apr 12, 2024 | 353 |
| NCT05369767Venous Thrombosis · China | 1 | UNKNOWN | Jan 30, 2023 | 64 |
How it is read
Names in the registry
- “SHR-2004 injection”, 6 entries
- “SHR-2004”, 1 entry
- “SAD, SHR-2004”, 1 entry
Codes read as this program: SHR2004.
Conditions, from the studies’ own filings
- Venous Thrombosis, 2 studies
- Atrial Fibrillation, 1 study
- Ovarian Neoplasms, 1 study
- Venous Thromboembolism, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.